Advertisement

Approach to Relapsed Refractory Myeloma

  • Joseph Mikhael
  • Shaji Kumar
  • S. Vincent Rajkumar
Chapter

Abstract

Despite tremendous advances in the initial management of patients with myeloma, now translating to at least a doubling of median overall survival in the last decade, this disease remains incurable in nearly all patients [1]. Although time to first relapse has been extended with superior induction, consolidation, and maintenance strategies, relapse is inevitable. With the emergence of many novel agents in the relapsed setting, options for providers and patients have dramatically increased. The optimal sequencing, combination, and dosing of these agents have yet to be determined. Indeed, with so many therapeutic options available, the clinician must have a rational, risk stratified and feasible to approaching patients in relapse.

This chapter provides an approach to therapy for the myeloma patient with relapsed and/or refractory disease. The detailed discussion of the data for the various treatment options in relapsed disease, including Stem Cell Transplantation, New Agents, and Biologic Therapy, is covered in subsequent chapters (see  Chaps. 10 13). The purpose of this chapter is to provide an overall strategy for the management of relapsed refractory disease and to help guide clinicians in selecting the most appropriate therapy for their patient. This approach emphasizes the heterogeneity of both the disease and the patient.

Keywords

Multiple Myeloma Relapse Disease Liposomal Doxorubicin Clinical Relapse Biochemical Relapse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88:225–35.CrossRefGoogle Scholar
  2. 2.
    Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23:2210–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067–76.PubMedCrossRefGoogle Scholar
  4. 4.
    Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8:479–91.PubMedCrossRefGoogle Scholar
  8. 8.
    Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Alexanian R, Gehan E, Haut A, Saiki J, Weick J. Unmaintained remissions in multiple myeloma. Blood. 1978;51:1005–11.PubMedGoogle Scholar
  10. 10.
    Madan S, Lacy MQ, Dispenzieri A, et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 2011; 118:1763–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Mateos MV, Oriol A, Martinez-Lopez J. Bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP): a randomised trial in elderly untreated patients with multiple myeloma older than 65 years. Lancet Oncol. 2010;11:934–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28:5101–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. N Engl J Med. 1999;341:1565–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5:112–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, Lopez C, Gonzalez M, San Miguel JF. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J. 2002;3:43–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003;122:607–16.PubMedCrossRefGoogle Scholar
  18. 18.
    Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999;21:319–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Osman K, Comenzo R, Rajkumar SV. Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344:1951–2.PubMedCrossRefGoogle Scholar
  21. 21.
    Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003;21: 4444–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.PubMedCrossRefGoogle Scholar
  25. 25.
    Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment]. N Engl J Med. 2005;352:2487–98.PubMedCrossRefGoogle Scholar
  26. 26.
    Richardson PG, Laubach J, Mitsiades C, et al. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology. 2010;24:22–9.PubMedGoogle Scholar
  27. 27.
    Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–901.PubMedCrossRefGoogle Scholar
  30. 30.
    Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105:8–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia. 1995;9:2115–8.PubMedGoogle Scholar
  32. 32.
    Gertz MA, Lacy MQ, Inwards DJ, et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999;23:221–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Russell SJ, Rajkumar SV. Multiple myeloma and the road to personalised medicine. Lancet Oncol. 2011;12:617–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360–76.PubMedCrossRefGoogle Scholar

Copyright information

© Mayo Foundation for Medical Education and Research 2014

Authors and Affiliations

  • Joseph Mikhael
    • 1
  • Shaji Kumar
    • 2
  • S. Vincent Rajkumar
    • 3
  1. 1.Division of Hematology and Medical OncologyMayo Clinic ArizonaScottsdaleUSA
  2. 2.Division of HematologyMayo ClinicRochesterUSA
  3. 3.Myeloma Amyloidosis Dysproteinemia Group, Division of HematologyMayo ClinicRochesterUSA

Personalised recommendations